CAR-PLT
LIVE

Serial Number

98105723

Owner

HemostOD SA

Attorney

Jonathan A. Hyman

Filing Date

Jul 27, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CAR-PLT Trademark

Serial Number: 98105723

CAR-PLT is a trademark filed by HemostOD SA on July 27, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

HemostOD SA

EPFL Innovation Park, Batiment M
Saint-Sulpice 1025 , CH

Entity Type: 99

Trademark Details

Filing Date

July 27, 2023

Registration Date

Not Registered

Published for Opposition

April 29, 2025

Goods & Services

Testing and analysis of blood plasma, red blood cells, white blood cells, blood platelets for scientific research purposes

Platelet-rich plasma therapy; blood banks

Medicinal infusions for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drugs for medical purposes, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Therapeutic drugs and agents, namely, pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion that facilitate the delivery of proteins, peptides, long and short RNA, siRNA, miRNA, and saRNA; Drug delivery agents in the form of infusion bags filled with platelets, infusion bags filled with platelets in suspension ready for infusion, infusion bags filled with lyophilized platelets, infusion bags filled with lyophilized platelets to be resuspended before infusion, infusion bags filled with cryopreserved platelets, infusion bags filled with cryopreserved platelets to be thawed prior to infusion consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Medicines for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Pre-filled syringes and infusion bags for medical purposes featuring pharmaceutical preparations for treating viral, inflammatory, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary dysfunction, oncological, hematological, hepatological, respiratory, neurological, gastrointestinal, hormonal, dermatological and immune system related diseases and disorders, blood disorders, cancers, and fibrotic and neurodegenerative diseases; Drug delivery agents infused in a patient's blood consisting of compounds that facilitate delivery of a wide range of pharmaceuticals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 5, 2026 EXRA
SOU EXTENSION 2 GRANTED
May 4, 2026 EX2G
SOU EXTENSION 2 FILED
May 4, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
May 4, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Oct 28, 2025 EXRA
SOU EXTENSION 1 GRANTED
Oct 27, 2025 EX1G
SOU EXTENSION 1 FILED
Oct 27, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Oct 27, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jun 24, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Apr 29, 2025 NPUB
PUBLISHED FOR OPPOSITION
Apr 29, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Apr 23, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 1, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Mar 31, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 31, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 31, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 31, 2025 CNEA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 17, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 17, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 17, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 16, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 16, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 16, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRN
NON-FINAL ACTION E-MAILED
Apr 17, 2024 GNRT
NON-FINAL ACTION WRITTEN
Apr 17, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 28, 2024 DOCK
PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED
Jan 12, 2024 AMPX
ASSIGNED TO LIE
Jan 12, 2024 ALIE
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 28, 2023 NWOS
TEAS VOLUNTARY AMENDMENT RECEIVED
Aug 21, 2023 PARI
NEW APPLICATION ENTERED
Jul 31, 2023 NWAP